Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 with Induction and Consolidation Chemotherapy in Older Adults with AML
NCT02582359Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose of MLN9708 in combination with induction chemotherapy at 1 year and Maximum Tolerated Dose / Recommended Phase 2 Dose of MLN9708 with combination with consolidation chemotherapy at 1 year. Started Jan 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02582359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582359.